Providence Capital Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Providence Capital Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-212	Closed	-$483	–	377
2024 Q2	$483	Hold	212	–	–	﹤0.01%	338
2024 Q1	$916	Hold	212	–	–	﹤0.01%	318
2023 Q4	$647	Hold	212	–	–	﹤0.01%	318
2023 Q3	$305	Hold	212	–	–	﹤0.01%	339
2023 Q2	$528	Hold	212	–	–	﹤0.01%	296
2023 Q1	$568	Buy	+212	New	+$1.02K	﹤0.01%	291

Providence Capital Advisors's GTHX Position: Q3 2024 in Review

Providence Capital Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 212 shares — an estimated $483 sold.

Providence Capital Advisors first reported a position in GTHX in Q1 2023 and held it in 6 quarters. The position peaked at $916 in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

Providence Capital Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Providence Capital Advisors sold 212 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $483.
Providence Capital Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Providence Capital Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $916 in Q1 2024.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Providence Capital Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.